Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke’s leadership team, Mr. Hoitt will be responsible for overseeing the Company’s global commercial strategy for STK-001. Recently announced data support the potential for STK-001 to be the first disease-modifying medicine for the treatment of Dravet syndrome.

"Jason brings deep expertise and a proven track record in successfully driving commercial strategies for novel new medicines and accelerating growth for companies as they transition to the commercial stage,” said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. “Jason’s experience building and leading teams, particularly in the area of rare disease, comes at the perfect time for Stoke as we plan for our registrational study of STK-001 and set our sights on the future where we aim to deliver the first potential disease-modifying medicine to patients with Dravet syndrome.”

“The recent data from the studies of STK-001 suggest that Stoke has the opportunity to change the way Dravet syndrome is treated by targeting the underlying cause of the disease, not just the symptoms,” said Mr. Hoitt. “I have been fortunate to have worked on some incredibly important advances in the treatment of severe diseases and look forward to bringing that experience and passion to Stoke. I am excited by the opportunity to build on the strong foundation of scientific innovation and clinical execution as we prepare the company to successfully conduct a registrational study and commercialize STK-001 and other potential new medicines in the future.”

Prior to joining Stoke, Mr. Hoitt served as Chief Commercial Officer at Provention Bio and led all commercial efforts including pre-launch and launch strategy and execution for Tzield (teplizumab-mzwv), the first drug approved to address the underlying autoimmune cause of type 1 diabetes. Prior to Provention Bio, Mr. Hoitt served as Chief Commercial Officer at Dova Pharmaceuticals and led all commercial efforts including launch strategy and execution for DOPTELET (avatrombopag) for chronic immune thrombocytopenia. Prior to Dova Pharmaceuticals, Mr. Hoitt was a member of the commercial leadership team at Insmed Incorporated, serving as a Vice President and Head of Sales. Mr. Hoitt also held senior sales, marketing and medical affairs roles at Sarepta Therapeutics, Vertex Pharmaceuticals and Gilead Sciences. Mr. Hoitt has held integral roles in the launch of several innovative medicines, including Arikayce (Insmed), Exondys 51 (Sarepta), and Incivek (Vertex). Mr. Hoitt holds a B.A. from the College of the Holy Cross.